ImageneBio, Inc. — Director's Dealing 2021

Dec 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-30

Reporting Person: Atlas Venture Fund XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, LLC (10% Owner)
Reporting Person: Atlas Venture Opportunity Fund I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	P	125000	$16.00	Acquired	874634	Indirect
2021-12-10	Common Stock	S	11989	$15.03	Disposed	1256224	Direct
2021-12-13	Common Stock	S	8330	$14.64	Disposed	1247894	Direct
2021-12-14	Common Stock	S	5959	$14.00	Disposed	1241935	Direct

Footnotes

F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture
Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is
the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).

F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.